Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.35 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455859 | 0.84 | BRD4 (0.55) | BRD4PTPN11L3MBTL1 | |
| SCHEMBL29455882 | 0.81 | BRD4 (0.45) | BRD4PTPN11L3MBTL1EEDPIK3C3 | |
| SCHEMBL31589747 | 0.81 | BRD4 (0.55) | BRD4L3MBTL1 | |
| SCHEMBL29455861 | 0.81 | BRD4 (0.44) | BRD4PTPN11L3MBTL1EEDPIK3C3 | |
| SCHEMBL29455769 | 0.81 | BRD4 (0.55) | BRD4PTPN11L3MBTL1EEDPIK3C3 | |
| SCHEMBL29455999 | 0.80 | BRD4 (0.60) | BRD4PTPN11L3MBTL1EEDPIK3C3 | |
| SCHEMBL29455977 | 0.80 | BRD4 (0.54) | BRD4PTPN11 | |
| SCHEMBL31590489 | 0.80 | BRD4 (0.56) | BRD4PTPN11BRD9BRD7L3MBTL1 | |
| SCHEMBL31590455 | 0.78 | BRD4 (0.58) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL29455720 | 0.78 | BRD4 (0.65) | BRD4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | BRD4 4/4885ADORA1 4635/4885PTPN11 4453/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | BRD4 6/4885ADORA1 4111/4885PTPN11 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.